Compare Aegon Ltd. (AEG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Novartis AG — how do they compare? Aegon Ltd. trades at $9.4 (market cap $14.16B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 21.1× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (4.9%). Which is the better fit depends on your goals.
| AEG | NVS | |
|---|---|---|
Market Cap | $14.16B | $298.18B |
Sector | Financials | Health |
52-Week High | $9.53 | $168.62 |
52-Week Low | $6.79 | $119.31 |
Enterprise Value | $15.31B | $339.50B |
Dividend Yield | 4.9% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.53, up 0.74% on the day, with a bullish technical signal driven by moving averages. The company reported revenue of $19.52 billion in 2024 with a net income margin of 3.64%, and recent earnings show mixed results with beats in Q2 and Q3 2025 but a miss in Q4. A dividend of $0.25 is scheduled for July 2026. The balance sheet shows total assets of $327.39 billion and a debt-to-asset ratio improving to 1.46 in 2024.
The outlook is cautiously optimistic with a P/E of 13.74 and P/S of 0.58 suggesting reasonable valuation, but risks include volatile cash flows and competitive pressures. Analyst sentiment is mixed with 27.78% buy ratings, highlighting potential for growth amid execution challenges.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
